ArticlebioRxiv : the preprint server for biology2025
Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis.
Meghan C Curtin, Abigail E Jackson, Elisabeth A Brown, J Alan Maschek, David Lum, James E Cox, Alana L Welm, Keren I Hilgendorf
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Meghan C CurtinDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, Utah 84112, USA.
Abigail E JacksonDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, Utah 84112, USA.
Elisabeth A BrownDepartment of Oncological Sciences, University of Utah School of Medicine; Salt Lake City, Utah, USA.
J Alan MaschekDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, Utah 84112, USA.
David LumHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
James E CoxDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, Utah 84112, USA.
Alana L WelmDepartment of Oncological Sciences, University of Utah School of Medicine; Salt Lake City, Utah, USA.
Keren I HilgendorfDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, Utah 84112, USA.ORCID 0000-0001-8377-8384 Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Alana L. Welm · 2017 to 2026
$13.5MCiliary signaling mechanisms regulating white adipose tissue expansionR01DK133455 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Keren Hilgendorf · 2022 to 2026
$1.9MHuntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training ProgramT32CA265782 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Donald E Ayer, Sheri L Holmen · 2023 to 2026
$1.0MAgilent 6550 QTOF system for U of UtahS10OD016232 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2013 to 2013
$578kQ-ToF Mass Spectrometer for the University of Utah MS and Proteomics CoreS10OD018210 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2015 to 2015
$530kAgilent 7200 GC/Q-TOF for the University of UtahS10OD021505 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2016 to 2016
$401kNCI NIH HHS P30 CA042014NCI NIH HHS T32 CA265782NCI NIH HHS U54 CA224076NIDDK NIH HHS R01 DK133455NIH HHS S10 OD016232NIH HHS S10 OD018210NIH HHS S10 OD021505
6 · The paper itselfAbstract
Obesity is predicted to become the largest modifiable risk factor for breast cancer in postmenopausal women, yet the mechanisms underlying this association are unclear. We identified a novel role for the endogenous oxylipin 9S-HODE, secreted by lean adipocytes, to induce ferroptosis in breast cancer cells while sparing normal breast epithelial cells. Obese adipocytes fail to secrete 9S-HODE, suggesting that the loss of ferroptosis induction significantly contributes to the acceleration of obesity-associated breast cancer. Consequently, the inhibition of ferroptosis accelerates breast cancer in lean, but not obese, mice. Further, 9S-HODE inhibits the growth of patient-derived breast cancer organoids, and supplementing 9S-HODE into tumors in obese mice is sufficient to reduce tumor burden, underscoring its potential as a therapeutic agent.
Identifiers
PMID40777459
PMCPMC12330663
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390